| |
 |
|
November 11, 2005
Aridis has signed for exclusive worldwide rights to a human monoclonal antibody to treat Pseudomonas aeruginosa infections. This antibody will be developed to treat chronic lung infections in cystic fibrosis patients and lung infections in hospital acquired pneumonia. Other potential indications include burns, eye and urinary tract infections. Combined with Aridis’ stabilization and delivery approach, this therapy could significantly improve life expectancy and quality of life for CF patients…More product info
October 15, 2005
Aridis is pleased to announce that Dr. Vu L. Truong has joined the company as Chief Technology Officer and Vice President of Research and Development. Dr. Truong, the former head of Formulation Technology Department at Medimmune Vaccines, has over ten years of experience in vaccines research and development and is among the world leader in proteins and vaccines stabilization strategies.
August 29, 2005
San Jose, CA - Aridis was awarded a $1 million SBIR biodefense grant by the National Institutes of Health (NIH) to develop a heat stable, oral vaccine for protection against typhoid fever. The award was for a two year period with a total budget of approximately $1M.
July 11, 2005
Aridis has signed an exclusive license for the multivalent human-bovine rotavirus vaccine for US, Europe and Canada from the National Institutes of Health (NIH). Aridis will develop the rotavirus vaccine with its own stabilization technology and a simple to administer oral delivery system that assures full dose receipt of the vaccine... More product info
|
|
|
 |
|
Aridis is a privately
held biopharmaceutical company formed in 2003, which uses pioneering formulation, processing, and delivery technologies to produce differentiated, high value products.
Aridis’ goal is to develop antibodies and vaccines that are more convenient and cost effective for both the recipient and the health professional by simplifying their storage and administration. Our initial products target infectious diseases that have a significant impact on life expectancy, such as infectious diseases in children and cystic fibrosis (CF) in adults and children. Aridis has three licensed products: two with preclinical data, and one with phase II clinical efficacy data. |
|
 |
| Infectious disease products in the forms of monoclonal antibodies and vaccines have become an attractive market segment for several reasons, including the increasing need for better therapies to address antibiotic resistance and the availability of more predictive preclinical animal models as compared other therapeutic areas, e.g., oncology.
The monoclonal antibody market has been one of the fastest growing segments in the biotechnology industry. Recent analyses indicate that this growth is expected to continue with an estimated tripling in value over the next six years from $10.3 billion to $30.3 billion. Introduction of new products will be responsible for much of this growth with arthritis, immune and inflammatory disorders among the leading indications. This market is evolving with more efficient manufacturing and delivery alternatives, i.e., pulmonary, spurring new treatments for a wider range of diseases. The lack of generic competition in the foreseeable future will provide a longer and more robust lifecycle than more traditional pharmaceuticals.
Vaccines are an expanding segment of the pharmaceutical market. In the last decade the vaccine market has grown from annual global sales of $1 billion to current estimates that range from $4 billion to almost $6 billion driven largely by the introduction of new vaccines. According to recent estimates an expected double-digit annual revenue growth in the vaccine market segment over the next decade could result in a $10 billion vaccine industry by 2010.
This growth will be dependent on introduction of new vaccines to protect against infectious diseases currently without treatment options, new combination vaccines and therapeutic vaccines for the treatment of cancer. Much of the growth will also be stimulated by new technological innovations to develop vaccine candidates with improved delivery options such as non-injectable routes of delivery (oral, nasal, transcutaneous).
|
|
|
|
